EW

SEC source: 0001225208-21-007973 · doc4.xml · nonDerivative · entry 1

BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,290.8505

F1 · balance_after: Does not reflect transactions effected on May 7, 2021 pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 1, 2021, which transactions were reported on a Form 4 filed with the SEC on May 7, 2021. The actual amount of securities beneficially owned by the Reporting Person following transaction reported on this Form 4 is 52,240.8505.

SEC source: 0001225208-21-007972 · doc4.xml · nonDerivative · entry 1

Chopra Daveen · CIK 0001740963 · CVP, Surgical Structural Heart

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,973

SEC source: 0001225208-21-007971 · doc4.xml · nonDerivative · entry 1

SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,033.6925

SEC source: 0001225208-21-007901 · doc4.xml · nonDerivative · entry 1

Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,901.2148

F1 · balance_after: Does not reflect transactions effected on May 7, 2021 pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 24, 2020, which transactions were reported on a Form 4 filed with the SEC on May 7, 2021. The actual amount of securities beneficially owned by the Reporting Person following transaction reported on this Form 4 is 30,512.2148.

SEC source: 0001225208-21-007900 · doc4.xml · nonDerivative · entry 1

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 142,340.138

SEC source: 0001225208-21-007899 · doc4.xml · nonDerivative · entry 1

Wood Larry L · CIK 0001440660 · CVP, TAVR

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 367,678.5231

SEC source: 0001225208-21-007651 · doc4.xml · derivative · entry 9

MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 65,550 shares

Expires 2021-05-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001225208-21-007651 · doc4.xml · nonDerivative · entry 7

MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Living Trust

Disclosed balance after: 3,147,787

SEC source: 0001225208-21-007651 · doc4.xml · nonDerivative · entry 5

MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 97,014.82

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 3, 2020.

F3 · price: This transaction was executed in multiple trades at prices ranging from $91.7250 to $92.7000. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001225208-21-007651 · doc4.xml · nonDerivative · entry 4

MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 130,464.82

SEC source: 0001225208-21-007651 · doc4.xml · nonDerivative · entry 3

MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 160,464.82

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 3, 2020.

F2 · price: This transaction was executed in multiple trades at prices ranging from $92.7400 to $93.5600. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001225208-21-007651 · doc4.xml · nonDerivative · entry 2

MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 162,564.82

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 3, 2020.

SEC source: 0001225208-21-007761 · doc4.xml · nonDerivative · entry 1

LAVIOLETTE PAUL A · CIK 0001191249 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,615

F1 · shares: These restricted stock units were granted on May 5, 2021 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the director ceases to serve on the Issuer's Board.

SEC source: 0001225208-21-007760 · doc4.xml · nonDerivative · entry 1

VALERIANI NICHOLAS J · CIK 0001263149 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,311

F1 · shares: These restricted stock units were granted on May 5, 2021 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the director ceases to serve on the Issuer's Board.

SEC source: 0001225208-21-007759 · doc4.xml · nonDerivative · entry 1

Sequeira Ramona · CIK 0001811081 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,918

F1 · shares: These restricted stock units were granted on May 5, 2021 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the director ceases to serve on the Issuer's Board.

SEC source: 0001225208-21-007758 · doc4.xml · nonDerivative · entry 1

Marsh Martha H. · CIK 0001500281 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,777

F1 · shares: These restricted stock units were granted on May 5, 2021 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the director ceases to serve on the Issuer's Board.

SEC source: 0001225208-21-007757 · doc4.xml · nonDerivative · entry 1

STONE HEISZ LESLIE · CIK 0001235408 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,180

F1 · shares: These restricted stock units were granted on May 5, 2021 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the director ceases to serve on the Issuer's Board.

SEC source: 0001225208-21-007756 · doc4.xml · derivative · entry 3

LORANGER STEVEN R · CIK 0001226924 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,270

Underlying: Common Stock · 3,270 shares

Expires 2028-05-04

F2 · derivative.exercise_date: These options were granted on May 5, 2021 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program and became fully exercisable on the grant date.

SEC source: 0001225208-21-007756 · doc4.xml · nonDerivative · entry 1

LORANGER STEVEN R · CIK 0001226924 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,580

F1 · shares: These restricted stock units were granted on May 5, 2021 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the director ceases to serve on the Issuer's Board.

SEC source: 0001225208-21-007712 · doc4.xml · derivative · entry 3

SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,250

Underlying: Common Stock · 4,250 shares

Expires 2028-05-03

F2 · derivative.exercise_date: These options were granted on May 4, 2021 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

SEC source: 0001225208-21-007712 · doc4.xml · nonDerivative · entry 1

SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,166.6925

F1 · shares: These restricted stock units were granted on May 4, 2021 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

SEC source: 0001225208-21-007711 · doc4.xml · derivative · entry 4

Wood Larry L · CIK 0001440660 · CVP, TAVR

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,700

Underlying: Common Stock · 5,700 shares

Expires 2028-05-03

F4 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 4, 2021 and scheduled to vest on May 4, 2024. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

SEC source: 0001225208-21-007711 · doc4.xml · derivative · entry 3

Wood Larry L · CIK 0001440660 · CVP, TAVR

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,700

Underlying: Common Stock · 44,700 shares

Expires 2028-05-03

F3 · derivative.exercise_date: These options were granted on May 4, 2021 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal monthly installments.

SEC source: 0001225208-21-007711 · doc4.xml · nonDerivative · entry 1

Wood Larry L · CIK 0001440660 · CVP, TAVR

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 368,357.5231

F1 · shares: These restricted stock units were granted on May 4, 2021 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

SEC source: 0001225208-21-007709 · doc4.xml · derivative · entry 5

MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,800

Underlying: Common Stock · 26,800 shares

Expires 2028-05-03

F4 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 4, 2021 and scheduled to vest on May 4, 2024. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

SEC source: 0001225208-21-007709 · doc4.xml · derivative · entry 4

MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 210,000

Underlying: Common Stock · 210,000 shares

Expires 2028-05-03

F3 · derivative.exercise_date: These options were granted on May 4, 2021 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal monthly installments.

SEC source: 0001225208-21-007709 · doc4.xml · nonDerivative · entry 1

MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 118,439.82

F1 · shares: These restricted stock units were granted on May 4, 2021 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

SEC source: 0001225208-21-007710 · doc4.xml · derivative · entry 3

WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,075

Underlying: Common Stock · 3,075 shares

Expires 2028-05-03

F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 4, 2021 and scheduled to vest on May 4, 2024. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

SEC source: 0001225208-21-007710 · doc4.xml · derivative · entry 2

WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,100

Underlying: Common Stock · 24,100 shares

Expires 2028-05-03

F2 · derivative.exercise_date: These options were granted on May 4, 2021 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal monthly installments.

SEC source: 0001225208-21-007710 · doc4.xml · nonDerivative · entry 1

WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 95,912.8064

F1 · shares: These restricted stock units were granted on May 4, 2021 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

SEC source: 0001225208-21-007708 · doc4.xml · derivative · entry 3

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,550

Underlying: Common Stock · 3,550 shares

Expires 2028-05-03

F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 4, 2021 and scheduled to vest on May 4, 2024. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

SEC source: 0001225208-21-007708 · doc4.xml · derivative · entry 2

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,800

Underlying: Common Stock · 27,800 shares

Expires 2028-05-03

F2 · derivative.exercise_date: These options were granted on May 4, 2021 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal monthly installments.

SEC source: 0001225208-21-007708 · doc4.xml · nonDerivative · entry 1

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 142,391.138

F1 · shares: These restricted stock units were granted on May 4, 2021 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

SEC source: 0001225208-21-007707 · doc4.xml · derivative · entry 5

BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Common Stock · 5,000 shares

Expires 2028-05-03

F4 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 4, 2021 and scheduled to vest on May 4, 2024. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

SEC source: 0001225208-21-007707 · doc4.xml · derivative · entry 4

BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,200

Underlying: Common Stock · 39,200 shares

Expires 2028-05-03

F3 · derivative.exercise_date: These options were granted on May 4, 2021 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal monthly installments.

SEC source: 0001225208-21-007707 · doc4.xml · nonDerivative · entry 1

BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,844.8505

F1 · shares: These restricted stock units were granted on May 4, 2021 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

SEC source: 0001225208-21-007706 · doc4.xml · derivative · entry 4

Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,375

Underlying: Common Stock · 6,375 shares

Expires 2028-05-03

F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 4, 2021 and scheduled to vest on May 4, 2024. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

SEC source: 0001225208-21-007706 · doc4.xml · derivative · entry 3

Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,400

Underlying: Common Stock · 44,400 shares

Expires 2028-05-03

F2 · derivative.exercise_date: These options were granted on May 4, 2021 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

SEC source: 0001225208-21-007706 · doc4.xml · nonDerivative · entry 1

Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,214

F1 · shares: These restricted stock units were granted on May 4, 2021 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

SEC source: 0001225208-21-007705 · doc4.xml · derivative · entry 3

Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,950

Underlying: Common Stock · 4,950 shares

Expires 2028-05-03

F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 4, 2021 and scheduled to vest on May 4, 2024. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

SEC source: 0001225208-21-007705 · doc4.xml · derivative · entry 2

Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,600

Underlying: Common Stock · 34,600 shares

Expires 2028-05-03

F2 · derivative.exercise_date: These options were granted on May 4, 2021 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

SEC source: 0001225208-21-007705 · doc4.xml · nonDerivative · entry 1

Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,940.2148

F1 · shares: These restricted stock units were granted on May 4, 2021 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

SEC source: 0001225208-21-007704 · doc4.xml · derivative · entry 3

Chopra Daveen · CIK 0001740963 · CVP, Surgical Structural Heart

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,025

Underlying: Common Stock · 4,025 shares

Expires 2028-05-03

F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 4, 2021 and scheduled to vest on May 4, 2024. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

SEC source: 0001225208-21-007704 · doc4.xml · derivative · entry 2

Chopra Daveen · CIK 0001740963 · CVP, Surgical Structural Heart

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,000

Underlying: Common Stock · 28,000 shares

Expires 2028-05-03

F2 · derivative.exercise_date: These options were granted on May 4, 2021 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

SEC source: 0001225208-21-007704 · doc4.xml · nonDerivative · entry 1

Chopra Daveen · CIK 0001740963 · CVP, Surgical Structural Heart

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,277

F1 · shares: These restricted stock units were granted on May 4, 2021 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

SEC source: 0001225208-21-007651 · doc4.xml · nonDerivative · entry 6

MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Living Trust

Disclosed balance after: 3,117,787

SEC source: 0001225208-21-007651 · doc4.xml · nonDerivative · entry 1

MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 97,014.82

SEC source: 0001225208-21-006982 · doc4.xml · nonDerivative · entry 1

SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 20,409

F1 · price: This transaction was executed in multiple trades at prices ranging from $97.6600 to $97.6800. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001225208-21-006981 · doc4.xml · derivative · entry 3

STONE HEISZ LESLIE · CIK 0001235408 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,671

Underlying: Common Stock · 10,000 shares

Expires 2023-07-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001225208-21-006981 · doc4.xml · nonDerivative · entry 2

STONE HEISZ LESLIE · CIK 0001235408 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,565

F1 · shares: The Issuer requires that upon vesting or exercise of equity awarded after 2011, each director is required to hold the underlying common stock (net of any shares sold to cover the exercise price and applicable taxes) until the director's Board service ends. These shares underlying the options exercised were sold to cover the exercise price and applicable taxes.